Follow
Mechanism of Action
Mechanism of action refers to the specific biological process through which the drug treats the underlying cause. It describes the more general response or effect of the drug. It is the interaction that allows a drug substance to produce it pharmacological effect.
FEB 20, 2017 | 8:00 AM
This is an introduction to the biological mechanism of RNA interference (RNAi) and experimental application of short, interfering RNA (siRNA). The key steps of the endogenous RNAi pathway wil...
FEB 24, 2016 | 10:00 AM
Every day, vast amounts of healthcare data are collected from clinical trials as well as real world medical visits on patient treatment regimens and subsequent clinical outcomes. This big dat...
DEC 09, 2015 | 10:00 AM
Date: December 9, 2015 10AM Pacific, 1PM Eastern
July 7, 2015, the U.S. Food and Drug Administration reviewed and approved ENTRESTO™ (sacubitril/valsartan) tablets to reduce the risk...
SEP 30, 2015 | 7:30 AM
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
SEP 09, 2015 | 9:00 AM
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
SEP 02, 2015 | 7:30 AM
This presentation will discuss fundamental physical, chemical, and biological concepts important to understanding control of detrimental biofilms. Four phenomena that are important in the act...
MAR 19, 2015 | 6:00 AM
This presentation will include both preclinical and small clinical studies with details on mechanism of action, safety and efficacy of a candidate drug that has the capability of alleviating...
JAN 26, 2015 | 8:00 AM
Advances in stem cell biology have raised great expectations that diseases of the central nervous system may be ameliorated by the development of non-haematopoietic stem cell medicines. Yet,...
SEP 16, 2014 | 10:00 AM
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
